Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure

References

• Petersen S, Rayner M, Wolstenholme J. Coronary Heart Disease Statistics: Heart Failure Supplement. London: British Heart Foundation, London, UK (2002).
   Google Scholar
• Fonarow GC. Heart failure: recent advances in prevention and treatment. Rev. Cardiovasc. Med. 1(1), 25–33, 54 (2000).
   PubMedGoogle Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341(8), 577–585 (1999).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Wood DA, Coats AJ et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83, 505–510 (2000).
   PubMed Web of Science ®Google Scholar
• Quinn M, Babb P, Brock A, Kirby L, Jones J. Cancer Trends in England and Wales 1950–1999. London: The Stationary Office, London, UK (2001).
   Google Scholar
• Williams H, Kearney M. Chronic heart failure. Pharmaceut. J. 296, 325–327 (2002).
   Google Scholar
• Petersen S, Rayner M, Wolstenholme J. Coronary Heart Disease Statistics: Heart Failure Supplement. London: British Heart Foundation (2002).
   Google Scholar
• Fonarow GC. Chronic heart failure: applying new findings to optimize care and improve survival. Rev. Cardiovasc. Med. 5(1), S1–S2 (2004).
   PubMedGoogle Scholar
• Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur. J. Heart Fail. 3, 283–291 (2001).
   PubMed Web of Science ®Google Scholar
• The National Collaborating Centre for Chronic Conditions. Chronic Heart Failure. National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Full version of NICE guideline No. 5 (2003).
   Google Scholar
• Hunt SA, Baker DW, Chin MH et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of chronic heart failure). J. Am. Coll. Cardiol. (2001).
   Google Scholar
• Pu CT, Johnson MT, Forman DE et al. Randomized trial of progressive resistance training to counteract the myopathy of chronic heart failure. J. Appl. Physiol. 90, 2341–2350 (2001).
   PubMed Web of Science ®Google Scholar
• NHS Centre for Review and Dissemination. Cardiac rehabilitation. Effective Health Care 4(4) (1998).
   Google Scholar
• Faris R, Flather M, Purcell H et al. Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int. J. Cardiol. 82, 149–158 (2002).
   PubMed Web of Science ®Google Scholar
• Lubsen J, Chadha DR, Yotof YT, Swedberg K. Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure. Am. J. Cardiol. 77, 1191–1196 (1996).
   PubMed Web of Science ®Google Scholar
• Beller B, Bulle T, Bourge RC et al. Lisinopril versus placebo in the treatment of heart failure: the Lisinopril Heart Failure Study Group. J. Clin. Pharmacol. 35, 673–680 (1995).
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N, Blood P. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews and randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 356, 1955–1964 (2000).
   PubMed Web of Science ®Google Scholar
• Flather MD, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 355, 1575–1581 (2000).
   PubMed Web of Science ®Google Scholar
• Abarca J, Malone DC, Armstrong EP, Zachry WM. Angiotensin-converting enzyme inhibitor therapy in patients with heart failure enrolled in a managed care organisation: effect on costs and probability of hospitalisation. Pharmacotherapy 24(3), 351–357 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz JS, Wang YR, Cleland JGF et al. High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the assessment of treatment with lisinopril and survival (ATLAS) trial. Am. J. Manag. Care 9(6), 417–424 (2003).
   PubMed Web of Science ®Google Scholar
• Bouzamondo A, Hulot JS, Sanchez P Cucherat M, Lechat P. β-blocker treatment in heart failure. Fundam. Clin. Pharmacol. 15, 95–109 (2001).
   PubMed Web of Science ®Google Scholar
• Shibata MC, Flather MD, Wang D. Systematic review of the impact of β blockers on mortality and hospital admissions in heart failure. Eur. J. Heart Fail. 3, 351–357 (2001).
   PubMed Web of Science ®Google Scholar
• Bonet S, Augusti A, Arnau JM et al. β-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch. Int. Med. 160, 621–627 (2000).
   PubMedGoogle Scholar
• Packer M, Antonopoulos GV, Berlin JA et al. Comparative effects of carvedilol and metropolol on left ventricular ejection fraction in heart failure: results of meta-analysis. Am. Heart J. 141, 899–907 (2001).
   PubMed Web of Science ®Google Scholar
• The β Blocker Evaluation of Survival Trial Investigation. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure. N. Engl. J. Med. 344, 1659–1667 (2001).
   PubMed Web of Science ®Google Scholar
• Chahoud G, Joseph J. β-blockade in chronic heart failure: does it work in everyone? Curr. Opin. Cardiol. 18, 400–405 (2003).
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Health Economics Group. Reduced costs with bisoprolol treatment for heart failure. An economic analysis of the second Cardiac Insufficiency Bisoprolol Study (CIBIS-II). Eur. Heart J. 22, 1021–1031 (2001).
   PubMed Web of Science ®Google Scholar
• Barry M. Cost–effectiveness of β blocker therapy for patients with chronic severe heart failure in Ireland. Ir. Med. J. 95(6), 174–177 (2002).
   PubMedGoogle Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. 341, 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Glick HA, Orzol SM, Tooley JF et al. Economic evaluation of the randomised aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc. Drugs Ther. 16, 53–59 (2002).
   PubMed Web of Science ®Google Scholar
• Tilson L, McGowan B, Ryan M, Barry M. Cost–effectiveness of spironolactone in patients with severe heart failure. Ir. J. Med. Sci. 172(2), 70–72 (2003).
   PubMed Web of Science ®Google Scholar
• The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N. Engl. J. Med. 336, 525–533 (1997).
   PubMed Web of Science ®Google Scholar
• van Veldhuisen DJ, Man in ‘t Veld AJ, Dunselman PH et al. Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT). J. Am. Coll. Cardiol. 22, 1564–1573 (1993).
   PubMed Web of Science ®Google Scholar
• Ward RE, Gheorghiade M, Young JB, Uretsky B. Economic outcomes of withdrawal of digoxin therapy in adult patients with stable congestive heart failure. J. Am. Coll. Cardiol. 26, 93–101 (1995).
   PubMed Web of Science ®Google Scholar
• John P, Demers C, Mc Kelvie RS, Liu PP. Angiotensin receptor blockers in heart failure: meta analysis of randomised controlled trials. J. Am. Coll. Cardiol. 39, 463–470 (2002).
   PubMed Web of Science ®Google Scholar
• Granger CB, Ertl G, Kuch J et al. Randomized trial of candersatan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. Am. Heart J. 139, 609–617 (2002).
   Web of Science ®Google Scholar
• Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group. Am. J. Cardiol. 85, 187–192 (2000).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345, 1667–1675 (2000).
   Web of Science ®Google Scholar
• Dasbach EJ, Rich MW, Segal R et al. The cost–effectiveness of losartan versus captopril in patients with symptomatic heart failure. Cardiology 91, 189–194 (1999).
   PubMed Web of Science ®Google Scholar
• Lip GY, Gibbs CR. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm. Cochrane Database Systematic Review CD003333 (2001).
   Google Scholar
• Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Int. Med. 154, 1449–1457 (1994).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Olson KL. Combined aspirin/ACE inhibitor treatment for CHF. Ann. Pharmacother. 35, 1653–1658 (2001).
   PubMed Web of Science ®Google Scholar
• Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Archibald DG, Ziesche S et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. 314, 1547–1552 (1986).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Johnson G, Ziesche S et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303–310 (1991).
   PubMed Web of Science ®Google Scholar
• Ghose JC, Chakraborty S, Mondal M, Bhandari B. Effect of vasodilator therapy on mortality in chronic congestive heart failure. J. Assoc. Physicians India 41, 269–271 (1993).
   PubMedGoogle Scholar
• Capomolla SC, Febo O, Ceresa M et al. Cost/utility ratio in chronic heart failure: comparison between heart failure management program delivered by day-hospital and usual care. J. Am. Coll. Cardiol. 40(7), 1259–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Jerant AF, Azari R, Nesbitt TS. Reducing the cost of frequent hospital admissions for congestive heart failure. A randomized trial of a home telecare intervention. Med. Care 39(11), 1234–1245 (2001).
   PubMed Web of Science ®Google Scholar
• Morimoto T, Hayashino Y, Shimbo T et al. Is B-type natriuertic peptide-guided heart failure management cost- effective? Int. J. Cardiol. 96, 177–181 (2004).
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC. Prevention of heart failure. Curr. Cardiol. Rep. 4, 194–199 (2002).
   PubMedGoogle Scholar
• Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J. Am. Coll. Cardiol. 39(11), 1780–1786 (2002).
   PubMed Web of Science ®Google Scholar
• Nordyke RJ, Kim JJ, Goldberg GA et al. Impact of anemia on hospitalisation time, charges, and mortality in patients with heart failure. Value Health 7(4), 464–471 (2004).
   PubMed Web of Science ®Google Scholar
• Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J. Card. Fail. 8(4), 216–224 (2002).
   PubMed Web of Science ®Google Scholar
• Benatar D, Bondmass M, Ghitelman J et al. Outcomes of chronic heart failure. Arch. Intern. Med. 163, 347–352(2003)
   PubMedGoogle Scholar
• Krum H, Liew D. New developments in the pharmacological treatment of chronic heart failure. Expert Opin. Investig. Drugs 12(5), 751–757 (2003).
   PubMed Web of Science ®Google Scholar